PTC reports results from infant SMA trial
PTC Therapeutics has released data from phase II of their FIREFISH trial of a treatment called Evrysdi (risdiplam) in infants with type 1 spinal muscular atrophy (SMA.)
SMA is a disorder which becomes evident around six months of age, resulting in very floppy, weak arms and legs, as well as difficulty swallowing and breathing. Infants with the disorder typically cannot sit upright without support, and the majority of the afflicted infants do not survive beyond the first few years of their life.
The second phase of the FIREFISH study involved a pivotal, single-armed clinical protocol in which 41 infants with type 1 SMA received the treatment for two years, followed by an open label extension. The treatment itself is a survival motor neuron 2-directed RNA splicing modifier, which in lay terms means the drug targets the chromosomal mutations that cause SMA.
The results indicate that after two years of treatment, 93% of the infants were alive, and 83% did not require permanent ventilation. No new deaths were recorded between 12 and 24 months, and 92% of the infants were still able to feed orally after two years. A maintenance of the ability to swallow was recorded in 95% of the infants.
Further, there were fewer hospitalizations required than in the natural course of the disease. The primary endpoint of this phase was that the majority of infants would be able to sit without needing support for a minimum of five seconds, after the first year of treatment.
The treatment was approved by the FDA in treating adults with SMA, as well as children aged two months and older.
Want to learn more?
In addition to reporting clinical trial news and stories from within the patient community, we operate Citrus, a fully integrated recruitment and retention software. Citrus fits any clinical trial and simplifies the implementation of patient engagement in your clinical trial. Whether you are already working with CTMS systems or not, Citrus is the perfect add-on to make patient interaction effective.
Since 2015, our team has been hard at work raising awareness of clinical trials across the globe. A Forbes ‘30 Under 30’ company and a graduate of the renowned Techstar program in New York, Citruslabs is at the forefront of patient recruitment and retention technologies. With over 3 million patients now recorded on our databases, our patient recruitment dashboard is fast becoming the most efficient method of trial recruitment.
Now a #1 health app in 17 countries, our Mindmate app is helping to revolutionize the way we think about healthcare. Mindmate “[takes] senior care into the digital age” (Forbes, 2018) by providing people with the cognitive decline the essential tools to help them rebuild and maintain strong mental health. Trusted by millions of users, our health community continues to grow as the content available expands to the needs of individuals today.
With more than 200 research sites now using the Citrus platform to screen thousands of patients every month, researchers are now well on their way to finding new treatments for hundreds of different health conditions - something that just would not be possible without a technological solution. Make sure that your clinical trial is in the lucky 12% and turn that luck into guaranteed results with Citrus.
Check out what our customers have to say about us here.
And If you’d like to know more about how Citruslabs can help you recruit more effectively, get in touch with our team here.